CPT: Pharmacometrics & Systems Pharmacology (Nov 2021)

CKD subpopulations defined by risk‐factors: A longitudinal analysis of electronic health records

  • Rajagopalan Ramaswamy,
  • Soon Nan Wee,
  • Kavya George,
  • Abhijit Ghosh,
  • Joydeep Sarkar,
  • Rolf Burghaus,
  • Jörg Lippert

DOI
https://doi.org/10.1002/psp4.12695
Journal volume & issue
Vol. 10, no. 11
pp. 1343 – 1356

Abstract

Read online

Abstract Chronic kidney disease (CKD) is a progressive disease that evades early detection and is associated with various comorbidities. Although clinical comprehension and control of these comorbidities is crucial for CKD management, complex pathophysiological interactions and feedback loops make this a formidable task. We have developed a hybrid semimechanistic modeling methodology to investigate CKD progression. The model is represented as a system of ordinary differential equations with embedded neural networks and takes into account complex disease progression pathways, feedback loops, and effects of 53 medications to generate time trajectories of eight clinical biomarkers that capture CKD progression due to various risk factors. The model was applied to real world data of US patients with CKD to map the available longitudinal information onto a set of time‐invariant patient‐specific parameters with a clear biological interpretation. These parameters describing individual patients were used to segment the cohort using a clustering approach. Model‐based simulations were conducted to investigate cluster‐specific treatment strategies. The model was able to reliably reproduce the variability in biomarkers across the cohort. The clustering procedure segmented the cohort into five subpopulations – four with enhanced sensitivity to a specific risk factor (hypertension, hyperlipidemia, hyperglycemia, or impaired kidney) and one that is largely insensitive to any of the risk factors. Simulation studies were used to identify patient‐specific strategies to restrain or prevent CKD progression through management of specific risk factors. The semimechanistic model enables identification of disease progression phenotypes using longitudinal data that aid in prioritizing treatment strategies at individual patient level.